GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (NSE:IPCALAB) » Definitions » Capex-to-Revenue

Ipca Laboratories (NSE:IPCALAB) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Ipca Laboratories Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Ipca Laboratories's Capital Expenditure for the three months ended in Dec. 2023 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was ₹20,528.60 Mil.

Hence, Ipca Laboratories's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Ipca Laboratories Capex-to-Revenue Historical Data

The historical data trend for Ipca Laboratories's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories Capex-to-Revenue Chart

Ipca Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.07 0.07 0.08 0.08

Ipca Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ipca Laboratories's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's Capex-to-Revenue falls into.



Ipca Laboratories Capex-to-Revenue Calculation

Ipca Laboratories's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-4944.7) / 62068.5
=0.08

Ipca Laboratories's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 20528.6
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipca Laboratories  (NSE:IPCALAB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Ipca Laboratories Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ipca Laboratories's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipca Laboratories (NSE:IPCALAB) Business Description

Traded in Other Exchanges
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a specialty and generic drug manufacturing company. The company's principal activity is Development, Manufacturing and Marketing of Pharmaceuticals Products. The company operates multiple subsidiaries with revenue generation split roughly between India and the rest of the world. Ipca's products are exported to more than 100 countries across the globe. Ipca has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories (NSE:IPCALAB) Headlines

No Headlines